Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.59 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.54 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.51 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.51 |
| ▸ | CYP3A43 | Q9HB55 | 2/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320710 | 0.85 | PIM1 (0.54) | METCHRNB2CHRNA4MAP4K3IRAK4 | |
| SCHEMBL15942449 | 0.85 | MAP4K3 (0.58) | METCHRNB2CHRNA4MAP4K3IRAK4 | |
| SCHEMBL3126749 | 0.85 | ALK (0.59) | ALKGSK3BDYRK1ACHRNB2CHRNA4 | |
| SCHEMBL24989566 | 0.84 | GSK3B (0.54) | ALKMETGSK3BDYRK1ACHRNB2 | |
| SCHEMBL2300261 | 0.84 | CHRNB2 (0.66) | ALKMETCHRNB2CHRNA4MAP4K3 | |
| Hydrochloric Acid SCHEMBL20135201 | 0.84 | ALK (0.58) | ALKGSK3BDYRK1ACHRNB2CHRNA4 | |
| SCHEMBL14638436 | 0.81 | ALK (0.65) | ALKCHRNB2CHRNA4MAP4K3IRAK4 | |
| SCHEMBL15324788 | 0.81 | IRAK4 (0.52) | ALKGSK3BDYRK1ACHRNB2CHRNA4 | |
| SCHEMBL20038308 | 0.78 | IRAK4 (0.58) | ALKMETCHRNB2CHRNA4MAP4K3 | |
| SCHEMBL6726843 | 0.78 | IRAK4 (0.58) | ALKMAP4K3IRAK4IRAK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2953940-B1 | PIPERIDIN-1-YL AND AZEPIN-1-YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2018-08-22 | — | — | EP | disclosed |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-06-29 | — | — | US | disclosed |
| US-9593106-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2017-03-14 | — | — | US | disclosed |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| CN-105189482-A | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | TAKEDA PHARMACEUTICAL | 2015-12-23 | — | — | CN | disclosed |
| EP-2953940-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014122474-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | WO | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | ALK 2599/4885MET 4878/4885GSK3B 3616/4885 |
| US-10030012-B2 | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists | CHRM1, CHRM2, CHRM4 | ALK 839/4885MET 1181/4885GSK3B 3803/4885 |
| US-20150376179-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | ALK 839/4885MET 1181/4885GSK3B 3803/4885 |
| US-20170183338-A1 | PIPERIDIN-1 -YL AND AZEPIN-1 -YL CARBOXYLATES AS MUSCARINIC M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | ALK 839/4885MET 1181/4885GSK3B 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.